Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million

Biohaven signed a licensing agreement with SK Biopharmaceuticals covering Biohaven’s epilepsy drug platform (including Opakalim) for potential consideration of up to $795 million. The deal is a positive commercial/valuation signal for Biohaven, though the magnitude depends on milestone timing and product uptake. Overall, it should be supportive for sentiment around the epilepsy pipeline.